Oxford Bioscience Partners News
Most Popular Oxford Bioscience Partners Story
VaxInnate gains $40M in third round
VaxInnate, which is developing new flu vaccines, has raised $40 million in its third round of venture capital. The company is relying on its Toll-like receptor technology to develop a new generation of vaccines that are far more effective and less expensive to produce than today's vaccines. New Leaf Venture Partners led the round, joined by Canaan Partners. Existing investors HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures, and CHL Medical Partners also participated in …
... Read more...Latest Headlines
- March 10, 2008
- October 25, 2007
- January 24, 2007
- January 18, 2007
- December 6, 2006
- November 27, 2006
- November 8, 2006
- October 24, 2006
- October 8, 2006
- December 19, 2005
- December 18, 2005
- August 29, 2005
- July 27, 2005
- July 14, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
